Compare PAR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAR | TRVI |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 887.7M | 1.5B |
| IPO Year | 1995 | 2019 |
| Metric | PAR | TRVI |
|---|---|---|
| Price | $14.52 | $11.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $36.00 | $20.38 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $455,547,000.00 | N/A |
| Revenue This Year | $11.10 | N/A |
| Revenue Next Year | $11.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 30.16 | N/A |
| 52 Week Low | $15.44 | $4.85 |
| 52 Week High | $72.15 | $14.39 |
| Indicator | PAR | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 29.00 | 43.88 |
| Support Level | N/A | $10.04 |
| Resistance Level | $38.44 | $11.78 |
| Average True Range (ATR) | 1.54 | 0.73 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 19.58 | 8.00 |
PAR Technology Corp is a foodservice technology company providing omnichannel cloud-based software and hardware solutions to the restaurant industry in three restaurant categories - quick service, fast casual, and table service - and the retail industry, including convenience and fuel retailers (C-Stores). The company's product and service offerings include point-of-sale, customer engagement and loyalty, digital ordering and delivery, operational intelligence, payment processing, hardware, and related technologies, solutions, and services. The company generates revenue from subscription service, Sale of Hardware products, and Professional Service.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.